Dr Ola Engkvist, AstraZeneca, outlines how deep learning architectures are being applied to drug discovery.
Applying Deep Learning Architectures to de novo Molecular Drug Design
Video Nov 20, 2018
Scientists from the University of Bristol, CNRS and Imophoron Ltd worked with the computer technology giant Oracle to develop a new kind of vaccine that needs no refrigeration. They used synthetic biology, cryo-electron microscopy and high-performance cloud computing to produce a candidate vaccine against the mosquito-borne chikungunya virus. Their findings could revolutionise the way vaccines are designed, developed and stored.WATCH NOW